[Effect of clinical pathway on advanced schistosomiasis patients with acites: a report of 220 cases].
To evaluate the effect of the clinical pathway on advanced schistosomiasis patients with acites. According to the Handbook of Schistosomiasis Control, and the Clinical Pathway on Advanced Schistosomiasis in Hubei Province, the therapeutic effects, disease awareness, and the satisfaction of patients of 220 advanced schistosomiasis patients (ascitic type) who were treated by the traditional pathway in 2013 and 220 patients who treated by the clinical pathway in 2014, respectively, were evaluated and compared with the statistical method. As the outcomes of the patients had no significant difference between the traditional pathway therapy and the clinical pathway therapy, the average hospitalization days and medical expense were reduced when the patients were treated by the clinical pathway. The average hospitalization days were reduced to 12 days from 14 days. The average medical expense was reduced to RMB 5,800 form RMB 6,400. The average rate of awareness about the disease and the satisfaction rate of the patients were raised to 95% in the patients treated by the clinical pathway. The results of t test for the three indicators above mentioned showed significant differences between the two therapies (all P < 0.05). The clinical pathway can standardize the medical behavior and avoid the waste of medical resources, so as to improve the treatment of advanced schistosomiasis.